NCT05501899View on ClinicalTrials.gov

Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Acute Lymphoblastic LeukemiaHepatotoxicity
Interventions
DRUG

Levocarnitine

Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)

Trial Locations (2)

92868

RECRUITING

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

RECRUITING

Children's Hospital of Orange County, Orange

All Listed Sponsors
collaborator

University of California, Irvine

OTHER

lead

Children's Hospital of Orange County

OTHER